Response to Paclitaxel in an Adult Patient with Advanced Kaposiform Hemangioendothelioma
Carregando...
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2016
Título da Revista
ISSN da Revista
Título do Volume
Editora
KARGER
Citação
CASE REPORTS IN ONCOLOGY, v.9, n.2, p.481-487, 2016
Resumo
Background: Kaposiform hemangioendothelioma (KHE) is a rare neoplasm of vascular origin that typically arises from the skin or soft tissues as a solitary tumor. The optimal therapy for this disease is still unknown. We report the case of an adult patient presenting with metastatic KHE of the spleen, who had a partial response after treatment with paclitaxel. Case Presentation: A 36-year-old man presented in November 2012 with a nontraumatic rupture of the spleen. A splenectomy was performed, and the pathology was consistent with a nonspecific vascular proliferation. Follow-up scans revealed lytic bone lesions and liver metastasis. A biopsy of the liver was performed and confirmed KHE. The decision was made to proceed with treatment with gemcitabine and docetaxel, which was discontinued due to myelotoxicity. The patient was then transferred to our institution, and a pathology review supported the diagnosis of metastatic KHE. His disease remained stable until February 2014, when he developed progression in the liver. Chemotherapy was restarted with paclitaxel, and a partial response was documented after 3 cycles. Unfortunately, disease progression occurred after 24 weeks, and subsequent treatments included prednisone, doxorubicin, interferon-a, gemcitabine, and ifosfamide, without any response. The patient developed Kasabach-Merritt phenomenon and passed away 1 week later due to a major gastrointestinal bleeding. Conclusions: This case report suggests that paclitaxel could be considered as a treatment option for advanced KHE, a rare condition for which no standard treatment exists. (C) 2016 The Author(s) Published by S. Karger AG, Basel
Palavras-chave
Kaposiform hemangioendothelioma, Sarcoma, Paclitaxel
Referências
- Angelo SPD, 2012, J CLIN ONCOL, V30, P9
- Barlow CF, 1998, J PEDIATR-US, V132, P527, DOI 10.1016/S0022-3476(98)70034-4
- Croteau SE, 2013, J PEDIATR-US, V162, P142, DOI 10.1016/j.jpeds.2012.06.044
- D'Angelo SP, 2015, ONCOLOGY-BASEL, V89, P205, DOI 10.1159/000381917
- Debelenko LV, 2005, MODERN PATHOL, V18, P1454, DOI 10.1038/modpathol.3800444
- Drolet BA, 2013, J PEDIATR-US, V163, P285, DOI 10.1016/j.jpeds.2013.03.080
- Funato M, 2013, HEAD NECK-J SCI SPEC, V35, P691
- Haisley-Royster C, 2002, J PEDIAT HEMATOL ONC, V24, P459, DOI 10.1097/01.MPH.0000016800.45769.B2
- Hardisson D, 2002, HEAD NECK-J SCI SPEC, V24, P614, DOI 10.1002/hed.10074
- Lisle JW, 2009, CLIN ORTHOP RELAT R, V467, P2464, DOI 10.1007/s11999-009-0838-2
- Mentzel T, 1997, AM J CLIN PATHOL, V108, P450
- Pasquier E, 2005, CANCER RES, V65, P2433, DOI 10.1158/0008-5472.CAN-04-2624
- Penel N, 2008, J CLIN ONCOL, V26, P5269, DOI 10.1200/JCO.2008.17.3146
- von Mehren M, 2012, CANCER-AM CANCER SOC, V118, P770, DOI 10.1002/cncr.26334
- Yu L, 2011, PATHOL ONCOL RES, V17, P969, DOI 10.1007/s12253-010-9331-1